FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Tom Daschle | influence | FDA update | FDA

Health groups try to steer FDA choice

Tools

We already know about the heated speculation on the identity of the next FDA commissioner. Now let's talk about the behind-the-scenes lobbying. As the Wall Street Journal reports this morning, health groups are doing some arm-twisting in an attempt to influence the appointment. Some 34 patient advocacy groups and research organizations--most of which get funding from pharma--have formed the FDA Commissioner Coalition and are urging President-elect Obama's transition team to tap someone who's familiar with the industry.

HHS chief-to-be Tom Daschle got a letter from the coalition saying that the next commissioner needs to be free of "pressure from elected and appointed officials and from the news media." And, the letter said, relationships with the pharma industry should be viewed as a "positive qualification" for the post.

Apparently, the groups are trying to undermine the urgings of some in Congress, who've asked Obama to populate FDA with agency outsiders and/or industry critics. Rep. Bart Stupak, who heads up the House Subcommittee on Investigations, wrote Obama in opposition to promoting any current FDA official to the top job; the agency's leadership now is "too close with the industries they regulate."

Even some of the coalition members that signed the letter wish it had included "industry" as one of the possible undue influences at FDA. As Marti Nelson Cancer Foundation's Bob Erwin told the WSJ, "I wish I had corrected the letter to include the importance of resisting pressure from companies, before signing."

- read the WSJ article

Related Articles:
Sharfstein looks to be on FDA short list
Add ex-Waxmanite to FDA hopefuls list
Sweep the FDA clean, Stupak says
Nissen takes a stand with the FDA
Daschle, Waxman nab pharma oversight power


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Tom Daschle   influence   FDA update   FDA  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.